|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
AR085404A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas de union a antigeno
|
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
WO2014122143A1
(en)
*
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
|
LT2961771T
(lt)
|
2013-02-26 |
2020-03-10 |
Roche Glycart Ag |
Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
KR102813659B1
(ko)
|
2013-11-11 |
2025-05-28 |
추가이 세이야쿠 가부시키가이샤 |
개변된 항체 가변영역을 포함하는 항원 결합 분자
|
|
EP3177643B1
(en)
|
2014-08-04 |
2019-05-08 |
F.Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP3204415B1
(en)
*
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
TWI831044B
(zh)
|
2014-11-11 |
2024-02-01 |
日商中外製藥股份有限公司 |
抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
|
|
PT3221356T
(pt)
|
2014-11-20 |
2020-10-29 |
Hoffmann La Roche |
Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
EP3150636A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
CN108778329B
(zh)
|
2016-02-17 |
2022-09-16 |
西雅图基因公司 |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
JP7015244B2
(ja)
*
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US10882918B2
(en)
|
2016-09-30 |
2021-01-05 |
Hoffmann-La Roche Inc. |
Bispecific T cell activating antigen binding molecules
|
|
WO2018067993A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP7267914B2
(ja)
*
|
2016-11-02 |
2023-05-02 |
エンクマフ エスアーエールエル |
Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
JP2020533383A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
EP3692066A2
(en)
|
2017-09-14 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CN111787938A
(zh)
|
2017-11-15 |
2020-10-16 |
诺华股份有限公司 |
靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
TW201938194A
(zh)
|
2017-12-05 |
2019-10-01 |
日商中外製藥股份有限公司 |
包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
|
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen binding molecules and methods of use
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
MA52212A
(fr)
|
2018-03-30 |
2021-02-17 |
Merus Nv |
Anticorps multivalent
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
EP3777895A4
(en)
*
|
2018-06-26 |
2021-12-22 |
ABL Bio Inc. |
ANTI-BCMA ANTIBODIES AND ASSOCIATED USE
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MX2021000827A
(es)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
|
|
EP4635978A2
(en)
|
2018-08-31 |
2025-10-22 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020053301A1
(en)
*
|
2018-09-11 |
2020-03-19 |
Ichnos Sciences S.A. |
Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
|
|
KR102337683B1
(ko)
*
|
2018-09-21 |
2021-12-13 |
주식회사 녹십자 |
고효율 항-tfpi 항체 조성물
|
|
US12509524B2
(en)
|
2018-09-28 |
2025-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region
|
|
US20220003772A1
(en)
|
2018-10-31 |
2022-01-06 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
CA3132587A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CN110229232B
(zh)
*
|
2019-06-19 |
2020-05-19 |
北京智仁美博生物科技有限公司 |
双特异性抗体及其用途
|
|
CN118547004A
(zh)
*
|
2019-06-19 |
2024-08-27 |
豪夫迈·罗氏有限公司 |
通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
|
|
CN114008212B
(zh)
*
|
2019-06-19 |
2024-12-06 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生三价抗体表达细胞的方法
|
|
CN120204384A
(zh)
|
2019-08-06 |
2025-06-27 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和相关方法
|
|
LT3819007T
(lt)
|
2019-11-11 |
2024-10-10 |
Amgen Research (Munich) Gmbh |
Dozavimo režimas, skirtas anti-bcma agentams
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
JP7773466B2
(ja)
|
2019-11-26 |
2025-11-19 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
|
|
CN114929343B
(zh)
*
|
2019-12-06 |
2025-03-18 |
瑞泽恩制药公司 |
用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021154534A1
(en)
*
|
2020-01-28 |
2021-08-05 |
Promab Biotechnologies, Inc. |
Plap-cd3 epsilon bispecific antibodies
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
EP4110376A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CR20220541A
(es)
*
|
2020-03-31 |
2022-11-28 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
PE20230470A1
(es)
*
|
2020-06-19 |
2023-03-14 |
Hoffmann La Roche |
Moleculas de union al dominio fc de activacion inmunitaria
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
CN114573703A
(zh)
*
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
US12084501B2
(en)
|
2021-03-24 |
2024-09-10 |
Janssen Biotech, Inc. |
Proteins comprising CD3 antigen binding domains and uses thereof
|
|
KR20230171944A
(ko)
*
|
2021-03-26 |
2023-12-21 |
자임워크스 비씨 인코포레이티드 |
시스테인 조작된 항체 작제물, 접합체 및 사용 방법
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
|
CN115521381B
(zh)
*
|
2021-06-24 |
2024-10-29 |
益科思特(北京)医药科技发展有限公司 |
结合bcma和cd3的双特异性抗体及其制备方法与应用
|
|
TW202323822A
(zh)
|
2021-08-03 |
2023-06-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
生藥組合物及穩定同位素標記肽之圖譜定位方法
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
|
KR20240099432A
(ko)
*
|
2021-11-10 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
이중특이성 bcma/cd3 항체를 포함하는 안정한 제형
|
|
US20260053939A1
(en)
|
2022-01-25 |
2026-02-26 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy for Cancer
|
|
US20260078195A1
(en)
|
2022-09-09 |
2026-03-19 |
Beijing Mabworks Biotech Co., Ltd |
Multi-specific antibody binding to bcma, gprc5d and cd3, and use thereof
|
|
EP4594355A1
(en)
*
|
2022-09-30 |
2025-08-06 |
Nona Biosciences (Suzhou) Co., Ltd. |
Cd3-targeting antibody and use thereof
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024100170A1
(en)
*
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
CN120303298A
(zh)
|
2022-12-05 |
2025-07-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
使用b细胞成熟抗原拮抗剂的治疗方法
|
|
CN118725113A
(zh)
*
|
2023-03-28 |
2024-10-01 |
三优生物医药(上海)有限公司 |
一种靶向cd3的抗体或其抗原结合片段及其用途
|
|
TW202517293A
(zh)
*
|
2023-07-07 |
2025-05-01 |
美商再生元醫藥公司 |
含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
|
|
CN121712524A
(zh)
*
|
2023-08-18 |
2026-03-20 |
百时美施贵宝公司 |
包含结合bcma和cd3的抗体的组合物以及治疗方法
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2026006492A2
(en)
|
2024-06-25 |
2026-01-02 |
Ypsilon Therapeutics, Inc. |
Anti-prame/hla-a2 antibodies and uses thereof
|
|
WO2026006495A1
(en)
|
2024-06-25 |
2026-01-02 |
Alloy Therapeutics, Inc. |
Anti-wt1/hla-a2 antibody and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
CN119241716A
(zh)
*
|
2024-09-13 |
2025-01-03 |
杭州百瑞竞康生物技术有限公司 |
结合CD235a和CD3的融合蛋白及其制备方法和用途
|